Search

Your search keyword '"Milhem M"' showing total 175 results

Search Constraints

Start Over You searched for: Author "Milhem M" Remove constraint Author: "Milhem M"
175 results on '"Milhem M"'

Search Results

2. 845P Vidutolimod + pembrolizumab as 2L+ treatment in patients with anti–PD-1–refractory melanoma and adrenal insufficiency: Subgroup analyses of a phase Ib study

5. Safety and Efficacy of RP1 + Nivolumab in Patients with Non-Melanoma Skin Cancer of the Head and Neck: Results From IGNYTE Phase 1/2 Multi-Cohort Clinical Trial

6. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

7. Oncogenic signaling pathways in the Cancer Genome Atlas

11. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft tissue sarcomas who are not candidates for chemotherapy

12. Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial

14. Results of phase I clinical trial of high doses of seleno-l-methionine (SLM) in sequential combination with axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients

15. Erratum: The Immune Landscape of Cancer (Immunity (2018) 48(4) (812–830.e14), (S1074761318301213), (10.1016/j.immuni.2018.03.023))

18. PB1737 MULTICENTER, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE AND FOOD EFFECT ON THE BIOAVAILABILITY OF CC-486 (ORAL AZACITIDINE) TABLETS IN ADULT CANCER PATIENTS

20. Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy

21. Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy

23. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

28. Five-year efficacy and safety update from METRIC: Trametinib vs chemotherapy in patients with BRAF V600E/K–mutant advanced or metastatic melanoma

29. Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma

34. Efficacy and safety of trabectedin or dacarbazine for the treatment of patients with uterine leiomyosarcoma after prior chemotherapy: A subgroup analysis of the randomized phase 3 SAR-3007 study

35. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

37. 1321 Efficacy and safety of trabectedin (T) or dacarbazine (D) in an elderly patient subgroup (65 years) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior chemotherapy

38. A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial

40. A Phase 1B/2, Multicenter, Open Label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec (T-Vec) and Ipilimumab (Ipi) Versus Ipi Alone in Previously Untreated, Unresected, Stage Iiib, Iiic, and Iv Melanoma

42. Efficacité du trametinib (T), sur la survie sans progression (SSP) et la survie globale (SG), en comparaison à la chimiothérapie (C) chez des patients (pts) ayant un mélanome métastatique (MM) avec mutation de BRAFV600E/K

45. The Effect of Perceived Transformational Leadership Style on Employee Engagement: The Mediating Effect of Leader’s Emotional Intelligence

48. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

49. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples

50. Comprehensive Characterization of Cancer Driver Genes and Mutations

Catalog

Books, media, physical & digital resources